Table 1 Study cohorts.
From: The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer
A: High-risk OC+OPMD discovery cohort | B: High-risk OC+OPMD cross-validation (A+27 samples) | C: Average-risk OC-only (OC subset of A + 7 average-risk) | D: Average-risk technical validation | Total unique across all cohorts | |
|---|---|---|---|---|---|
Number of participants | 117 | 144 | 99 | 91 | 242 |
Controls | 59 | 75 | 49 | 91 | 171 |
Cases | 58 | 69 | 50 | n/a | 71 |
Number of samples total | 117 | 117 from Cohort A+ | 92 from Cohort A+ | 282 | n/a |
Unique samples | 117 | 27 | 7 | 282 | 433 |
Cases | 58 | 69 | 50 | n/a | 71 |
Pre-malignant | 10 | 14 | n/a | n/a | 14 |
Malignant | 48 | 55 | 50 | n/a | 57 |
Sex (% female) | 37.6 | 37.5 | 40.4 | 38.7 | 38.8 |
Controls | 54.2 | 50.7 | 57.1 | 38.7 | |
Cases | 20.7 | 23.2 | 24 | n/a | |
Age (y) mean ± std | 60.2 ± 11.3 | 61.4 ± 11.4 | 59.7 ± 12.6 | 22.6 ± 10.5 | 37.2 ± 21.7 |
Controls | 56.3 ± 10 | 58.5 ± 11 | 56 ± 10.8 | 22.6 ± 10.5 | |
Cases | 64.1 ± 11.4 | 64.5 ± 11.1 | 63.3 ± 13.3 | n/a |
